reference pricing

What will be the impact of adopting reference pricing in the US?

That is the question that a recent JAMA study–Mulcahy et al. (2021)–aim to answer. The authors use IQVIA MIDAS data to estimate sales price and volume in the US. These can can be used to estimate drug wholesale acquisition cost (WAC), but they ignore rebates. To account for rebates in the US they use SSR …

What will be the impact of adopting reference pricing in the US? Read More »

International Reference Pricing: List vs. Net Pricing issues

Leah Rand and Aaron Kesselheim have an interesting commentary in Value in Health reviewing some of the challenges of implementing international reference pricing (IRP) in the U.S. IRP would set drug prices in the U.S. as no higher than a basket of drug prices in other developed countries. This issue is of particular interest due …

International Reference Pricing: List vs. Net Pricing issues Read More »